Jacob Smith30 Mar 2026Novartis Deal Novartis is planning a $2 billion acquisition of biotech firm Excellergy, betting big on next-generation allergy treatments. The move underscores growing competition and innovation in the global pharmaceutical sector. #Novartis #Biotech #Pharma #Healthcare #Investment #Innovation5 likes5 comments#biotech#novartis#investment#innovation#healthcare
